Adverse events (in more than 5% of participants) | Placebo | 120 mg (80 mg) | 240 mg (160 mg) | |||
n | % | n | % | n | % | |
Infections and infestations | 32 | 55.2 | 24 | 43.6 | 24 | 42.1 |
Gastrointestinal disorders | 18 | 31.0 | 12 | 21.8 | 15 | 26.3 |
Nervous system disorders | 14 | 24.1 | 13 | 23.6 | 13 | 22.8 |
Investigations | 12 | 20.7 | 5 | 9.1 | 6 | 10.5 |
Skin and subcutaneous tissue disorders | 8 | 13.8 | 6 | 10.9 | 6 | 10.5 |
Psychiatric disorders | 5 | 8.6 | 6 | 10.9 | 8 | 14.0 |
General disorders and administration site conditions | 5 | 8.6 | 7 | 12.7 | 6 | 10.5 |
Respiratory, thoracic, and mediastinal disorders | 4 | 6.9 | 7 | 12.7 | 2 | 3.5 |
Musculoskeletal and connective tissue disorders | 2 | 3.4 | 5 | 9.1 | 5 | 8.8 |
Eye disorders | 4 | 6.9 | 3 | 5.5 | 1 | 1.8 |
Injury, poisoning and procedural complications | 0 | 0 | 4 | 7.3 | 3 | 5.3 |
Serious adverse events | n | n | n | |||
Suicidal ideation | 1 | 1 | ||||
Altered state of consciousness | 1 | |||||
Skin laceration | 1 | |||||
Salmonellosis | 1 |